US Pharm. 2014;38(3):HS-16.
Research on cervical cancer performed by a physician at the University of Arizona Cancer Center at St. Joseph’s Hospital and Medical Center is expected to change the standard of care for women with advanced cervical cancer. The results of the multisite research project by Bradley J. Monk, MD, published in the New England Journal of Medicine, revealed that women with advanced cervical cancer live about 4 months longer with the combined use of bevacizumab (Avastin) and chemotherapy compared to women on chemotherapy alone (17 months vs. 13.3 months, respectively).
“There has been a large unmet medical need for active treatments for cervical cancer,” says Dr. Monk. “We believe the results of this study are a significant step forward and now we will move to trying to add bevacizumab to a front-line treatment when cancers are more curable, rather than using it at the time of recurrence.”
